Disease Overview:Hepatorenal syndrome(HRS)
Hepatorenal syndrome (HRS) is a life-threatening complication of advanced liver disease—most commonly cirrhosis with ascites—characterized by progressive renal vasoconstriction, reduced glomerular filtration rate, and functional acute kidney injury without intrinsic renal pathology. It is classified into two types: Type 1 HRS, marked by rapid deterioration in renal function (serum creatinine doubling to >2.5 mg/dL within days), and Type 2, associated with refractory ascites and slower, chronic renal impairment. Diagnosis requires strict exclusion of other causes of renal failure—including prerenal azotemia, intrinsic nephropathy, and obstructive uropathy—and adherence to international criteria (e.g., ICA-AASLD guidelines). Prognosis remains poor without intervention, with median survival under two weeks for untreated Type 1 HRS.
China offers distinct advantages in managing HRS: leading hepatology and nephrology centers—such as Beijing Union Medical College Hospital and Shanghai Renji Hospital—employ multidisciplinary teams experienced in complex liver-kidney interactions, utilize advanced hemodynamic monitoring (e.g., transpulmonary thermodilution), and routinely perform terlipressin-based pharmacotherapy alongside albumin infusion and, where indicated, transjugular intrahepatic portosystemic shunt (TIPS) or align with global benchmarks: published cohort studies report 60–75% short-term reversal rates in Type 1 HRS with protocol-driven therapy. Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based standards. As a dedicated medical tourism agency, we facilitate seamless access for international patients—vetting accredited hospitals, coordinating specialist consultations, clarifying all-inclusive pricing upfront, and providing end-to-end support from visa assistance to post-treatment follow-up.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Hepatorenal Syndrome (HRS) — Nephrology Department
I. Non-Surgical / Conservative / Medication-Based Management
*Target Criteria*: Type 1 HRS (acute renal failure in cirrhosis), serum creatinine ≥1.5 mg/dL, no shock, no nephrotoxic drugs, urine sodium <10 mmol/L, absence of parenchymal kidney disease.
- •Terlipressin + Albumin Regimen (First-Line)
- Human Albumin (20% IV, 100 g/day × 3 days): ¥420–¥630/day (¥12.6–¥18.9 USD) - Daily monitoring (BUN, Cr, Na⁺, BP, urine output): ¥180/day (¥5.4 USD) - *Total 3-day course*: ¥4,500–¥7,500 (¥135–¥225 USD)
- •Midodrine + Octreotide + Albumin (Alternative)
- Octreotide (SC/IV): ¥360–¥540/day (¥10.8–¥16.2 USD) - Albumin (same as above): ¥420–¥630/day - *Total 3-day course*: ¥2,700–¥4,200 (¥81–¥126 USD)
- •Diagnostic & Monitoring Labs (Baseline + Daily)
- Urine sodium/osmolality: ¥160 (¥4.8 USD) - Abdominal ultrasound (liver/kidney morphology): ¥280 (¥8.4 USD)
II. Procedural / Interventional Options
*Eligibility*: Refractory Type 1 HRS despite pharmacotherapy; MELD ≥15; no active sepsis or uncontrolled GI bleeding.
- •Transjugular Intrahepatic Portosystemic Shunt (TIPS)
- TIPS procedure (stent placement + hemodynamic assessment): ¥28,000–¥42,000 (¥840–¥1,260 USD) - Post-op ICU monitoring (24–48 h): ¥1,800–¥2,400/day (¥54–¥72 USD)
- •Liver Transplantation (Definitive Therapy)
- Transplant surgery + 7-day ICU/stay: ¥320,000–¥480,000 (¥9,600–¥14,400 USD) - *Note: HRS reversal post-transplant occurs in >85% of survivors.*
III. Special/Complex Scenarios
- •HRS with Acute-on-Chronic Liver Failure (ACLF): Requires CRRT support (¥1,200–¥1,800/day; ¥36–¥54 USD) + ICU admission (¥2,400/day; ¥72 USD).
- •Recurrent HRS post-TIPS: Consider salvage transplant or palliative albumin infusions (¥1,260/week; ¥38 USD).
Quick Selection Guide
- •<60 years, MELD ≤20, budget <¥10,000: Start terlipressin + albumin (¥135–¥225 USD); monitor closely.
- •MELD ≥25, refractory to meds, no contraindications: Proceed to TIPS (¥840–¥1,260 USD) — improves 1-year survival by 35%.
- •Age 60–75, comorbid diabetes/CAD, MELD ≥30: Prioritize liver transplant evaluation (¥9,600–¥14,400 USD); avoid TIPS if cardiac reserve poor.
- •>75 years or frailty with ACLF grade 3: Focus on supportive care (albumin + diuretic optimization) — average cost ¥3,600/month (¥108 USD).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Hepatorenal syndrome Medical Vacation Packages
Curated transparent all-inclusive packages combining Hepatorenal syndrome treatment with China top medical destinations: